NCT07139548尚未招募3 期
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes
Guangdong Raynovent Biotech Co., Ltd1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2025年8月31日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 600
- 试验地点
- 1
- 主要终点
- Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg)
研究概览
简要总结
The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have been diagnosed with type 2 diabetes mellitus (T2DM)
- •Have HbA1c between ≥7.0% and ≤11.5%
- •Have a body mass index (BMI) ≥20 kilograms per meter squared (kg/m²) at screening
- •Be of stable weight (±5%) for at least 12 weeks before screening
排除标准
- •Have type 1 diabetes mellitus
- •Presence of severe chronic diabetic complications at screening, including but not limited to: proliferative diabetic retinopathy, diabetic macular edema, and severe non-proliferative diabetic retinopathy requiring acute treatment;
- •History of diabetic ketoacidosis or hyperosmolar hyperglycemic state within 24 weeks prior to randomization;
- •Occurrence of a Grade 3 hypoglycemic event within 12 months prior to screening, or ≥3 Grade 2 hypoglycemic events (venous or capillary blood glucose <3.0 mmol/L) within 3 months prior to screening, or presence of hypoglycemia-related symptoms ;
- •History of severe trauma, severe infection, or surgery within 12 weeks prior to screening that may affect glycemic control;
- •Receipt of blood transfusion within 12 weeks prior to screening, or blood donation/loss ≥400 mL within 12 weeks prior to screening, or blood donation/loss ≥200 mL within 4 weeks prior to screening, or known hemoglobinopathy (such as thalassemia, hemolytic anemia, sickle cell anemia, etc.);
- •Any unstable or treatment-requiring endocrine disorders related to glycemic control other than type 2 diabetes mellitus (such as hyperthyroidism, acromegaly, Cushing's syndrome, etc.).
研究组 & 干预措施
6mg RAY1225
Experimental
6 milligrams (mg) RAY1225 administered subcutaneously (SC) once every two week.
干预措施: RAY1225 (Drug)
9mg RAY1225
Experimental
9 mg RAY1225 administered subcutaneously (SC) once every two week.
干预措施: RAY1225 (Drug)
1 mg Semaglutide
Active Comparator
1 mg semaglutide administered SC once a week.
干预措施: Semaglutide (Drug)
结局指标
主要结局
Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg)
时间窗: Baseline,36 Week
HbA1c is the glycosylated fraction of hemoglobin A.
次要结局
- Percentage of Participants Achieving an HbA1c Target Value of <7%(Baseline,36 Week)
- Mean change in fasting serum glucose(Baseline,36 Week)
- Proportion of patients who achieved weight loss of >5%, >10%, and >15% from baseline(Baseline,36 Week)
- Percentage of Participants With HbA1c Target Value of <6.5%(Baseline,36 Week)
- Percentage of Participants With HbA1c Target Value of <5.7%(Baseline,36 Week)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 DiabetesType 2 DiabetesNCT03987919Eli Lilly and Company1,879
已完成
3 期
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)Rheumatoid ArthritisNCT01217086Celltrion617
尚未招募
3 期
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 DiabetesType 2 Diabetes MellitusNCT06339086Chengdu Brilliant Pharmaceutical Co., Ltd.478
终止
3 期
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedAcute Myeloid LeukemiaNCT04778397Gilead Sciences258
已完成
1 期
Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy MenDiabetes Mellitus, Type 2NCT03638778Novo Nordisk A/S105